BMB’s new primer in its Bonevolent™ line of technology has been granted a patent in China
Press release: Biomedical Bonding's unique primer formulation to enable strong adhesion between difficult substrates such as wet bone and metals to its resin-based composite has been granted a patent in China. The primer is an important part of BMB’s Bonevolent™ technology that enables surgeons to do on-site customizable bone fracture fixations.
Biomedical Bonding AB has secured an additional patent in China based on a unique primer formulation for use together with its resin-based composite technology directly on wet bone substrates or metal implants. The patent in China is an important step toward the commercialization of BMB’s Bonevolent™ line of products that will introduce a new paradigm in bone fracture fixation. The Bonevolent™ technology has the advantage of being customizable by the surgeon and enables patient-specific adaptation to the fracture and bone geometry. The technology does also have a unique biocompatible, not causing any irritation or soft tissue adhesion which is a common issue with metal implants leading to patient discomfort and post-surgery complications.
“BMB continuous to expand its Bonevolent™ IPR portfolio in key geographical positions in which China is considered as an attractive market for the company’s fracture fixation products. With this patent approved, the IPR for our primer technology is further strengthened as it protects all key components facilitating exceptional resins-based fixation of bones, metal or teeth. As a company, such approval is a crucial element and allows BMB to pursue the commercialization of its composite-based fixators towards patient-customized treatment of both bone fractures as well dental restorations”, says Founder and CEO, Prof. Michael Malkoch.
For more information, please contact:
Michael Malkoch, CEO and Founder
Phone: +46 (0) 8 121 56 755
E-mail: michael.malkoch@biomedicalbonding.com
Homepage: www.biomedicalbonding.com
Biomedical Bonding AB is a platform based Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.
